Recro Pharma从美国政府获得150万美元的配方开发和制造合同

07:51 AM EST, 01/26/2022 (MT Newswires) -- Recro Pharma (REPH) was awarded a development and manufacturing contract from the US government to support clinical development of a skin-cancer treatment.

Under terms of the multi-year, $1.5 million contract, the company will formulate, manufacture and supply a topical dermal drug and a placebo for a planned cancer prevention clinical study.

The trial is designed to evaluate the effects of the investigational compound on the recurrence of basal cell carcinoma.